Effects of galantamine on behavioural and psychological disturbances and caregiver burden in patients with Alzheimer's disease

References

• Cummings JL, McPherson S. Neuropsychiatric assessment of Alzheimer’s disease and related dementias. Aging 2001;13(3):240–6
   PubMedGoogle Scholar
• Durand PJ, Krueger PD, Chambers LW, Grek A, Charles C. Predictors of caregivers’ dissatisfaction with community long-term care services for seniors: results from the Canadian Study of Health and Aging (CSHA). Can J Public Health 1995;86:325–32
   Google Scholar
• Cummings J. Cholinesterase inhibitors: expanding applications. Lancet 2000;356:2024–5
   PubMed Web of Science ®Google Scholar
• Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. Donepezil MSAD Study Investigators Group. A 24-week, randomised, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology 2001;57: 613–20
   Google Scholar
• Tariot PN, Cummings JL, Katz IR, et al. A randomised double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer’s disease in the nursing home setting. J Am Geriatr Soc 2001;49:1590–9
   PubMed Web of Science ®Google Scholar
• Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomised, placebo-controlled trial of galantamine in AD. Neurology 2000;54:2269–76
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease. Lancet 2002;359:1283–90
   PubMed Web of Science ®Google Scholar
• Roesler M, Retz W, Retz-Jungingen P, Dennler HJ. Effects of two-year treatment with cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer’s disease. Behav Neurol 1999;11:211–6
   Google Scholar
• Bullock R et al. Effects of rivastigmine on behavioural symptoms in nursing home patients with Alzheimer’s disease. Int Psychogeriatr 2001;13(Suppl 2):242
   Google Scholar
• Perry EK, Morris CM, Court JA, et al. Alteration in nicotine binding sites in Parkinson’s disease, Lewy body dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience 1995;64:385–95
   PubMed Web of Science ®Google Scholar
• Fu Y, Matta SG, Gao W, Sharp BM. Local a-bungarotoxin-sensitive nicotinic receptors in the nucleus accumbens modulate nicotine-stimulated dopamine secretion in vivo. Neuroscience 2000;101(2):369–75
   PubMed Web of Science ®Google Scholar
• Court JA, Piggott MA, Lloyd S, et al. Nicotinic binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience 2000;98(1):79–87
   PubMed Web of Science ®Google Scholar
• Picciotto MR, Zoli M. Nicotinic receptors in aging and dementia. J Neurobiol 2002;53:641–55
   PubMedGoogle Scholar
• Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 2002;53:590–605
   Google Scholar
• Berg DK, Conroy WG. Nicotinic a-7 receptors: synaptic options and downstream signaling in neurons. J Neurobiol 2002;53:512–23
   PubMedGoogle Scholar
• Pereira EFR, Hilmas C, Santos MD, Alkondon M, Maelicke A, Albuquerque EX. Unconventional ligands and modulators of nicotinic receptors. J Neurobiol 2002;53:479–500
   PubMedGoogle Scholar
• Albuquerque EX, Alkondon M, Pereira EFR, et al. Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. J Pharmacol Exp Ther 1997;280:1117–36
   PubMed Web of Science ®Google Scholar
• Alkondon M, Braga MF, Pereira EF, Maelicke A, Albuquerque EX. a7-Nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus. Eur J Pharmacol 2000;393: 59–67
   Google Scholar
• Alkondon M, Pereira EF, Eisenberg HM, Albuquerque EX. Nicotinic receptor activation in human cerebral cortical interneurons: a mechanism for inhibition and disinhibition of neuronal networks. J Neurosci 2000;20:66–75
   PubMed Web of Science ®Google Scholar
• Santos MD, Alkondon M, Pereira EFR, et al. The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammelian central nervous system. Mol Pharmacol 2002;61:1222–34
   PubMed Web of Science ®Google Scholar
• Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer’s disease. Biol Psychiatry 2001;49:279–88
   PubMed Web of Science ®Google Scholar
• Maelicke A. Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer’s disease. Dementia Geriatr Cogn Disord 2000;11\(Suppl 1):11–8
   Google Scholar
• Lazarewicz M, Spiros A, Finkel L, Carr R, Geerts H. The virtual synaptic cleft model, 2001 [data on file]. Understanding the cholinergic effects of reminyl using a virtual synaptic cleft. The International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, 2002
   Google Scholar
• Spiros A, Lazarewicz MT, Zhang L, et al. Galantamine increases dopamine output: insights using a virtual cross-talk model. ICAD 2002. Poster presentation. The International Conference on Alzheimer’s Disease and Related Disorders, Stockholm, 2002
   Google Scholar
• Granon S, Passetti F, Thomas KL, Dalley JW, Everitt BJ, Robbins TW. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. J Neurosci 2000;20:1208–15
   PubMed Web of Science ®Google Scholar
• Meyer JH, Kruger S, Wilson AA, et al. Lower dopamine transporter binding potential in striatum during depression. NeuroReport 2001;12:4121–5
   PubMed Web of Science ®Google Scholar
• Labarca C, Schwarz J, Deshpande P, et al. Point mutant mice with hypersensitive a4 nicotinic receptors show dopaminergic deficits and increased anxiety. Proc Natl Acad Sci, USA 2001;98:2786–91
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind E, Wessel T, Yuan W, The Galantamine USA-1 Study Group. Galantamine in AD: a 6-month, randomised, placebo-controlled trial with a 6-month extension. Neurology 2000;54: 2261–8
   Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer’s disease: a multicenter randomised controlled trial. Br Med J 2000;321:1445–8
   Google Scholar
• Rockwood K, Mintzer J, Truyen L, Wessel T, Wilkinson D. Effects of a flexible galantamine dose in Alzheimer’s disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589–95
   Google Scholar
• Erkinjuntti T, Lilienfeld S. Galantamine demonstrates broad clinical efficacy over 12 months in patients with Alzheimer’s disease with cerebrovascular disease and probable vascular dementia. [AAN 2002; Poster presentation]. Neurology 2002;58(7, Suppl 3): 278 [poster P04.047]
   Google Scholar
• McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS/ADRDA Work Group* under the auspices of the Department of Health and Human Services task force on Alzheimer’s disease. Neurology 1984;34:939–44
   PubMed Web of Science ®Google Scholar
• Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gombein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44:2308–14
   Google Scholar
• Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer’s Disease Cooperative Study – clinical global impression of change. Alzheimer Dis Assoc Disord 1997;1(Suppl 2):22–32
   Google Scholar
• Brunner C, Spiegel R. Eine Validierungsstudie mit der NOSGER (Nurses’ Observation Scale for GERiatric Patients), einem neuen Beurteilungsinstrument fuer die Psychogeriatrie. Z Klin Psychol 1990;19:211–29
   Google Scholar
• Folstein MF, Flstein SE, McHugh PR. “Mini-Mental State”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12: 189–98
   Google Scholar
• WHO ICD-10 classification of mental and behavioural disorders. Geneva: World Health Organization; 1992
   Google Scholar
• Lang CJG, Hager K, Roesler M, Rettig K, Schwalen S. Cognitive and behavioural benefits with 6months of galantamine (Reminyl) treatment in patients with mild Alzheimer’s disease results in reduced caregiver stress. ICAD 2002; [Poster presentation]
   Google Scholar
• Robert Ph. Understanding and managing behavioural symptoms in Alzheimer’s disease and related dementias: focus on rivastigmine. Curr Med Res Opin 2002;18:156–71
   PubMed Web of Science ®Google Scholar
• Winblad B, Engedal K, Soininen H, et al. A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001;57:489–95
   PubMed Web of Science ®Google Scholar
• Cummings JL. Cholinesterase inhibitors: a new class of psychotropic compounds. Am J Psychiatry 2000;157:4–15
   PubMed Web of Science ®Google Scholar
• Dani JA. Overview of nicotinic receptors and their roles in the central nervous system. Soc Biol Psychiatry 2001;49:166–74
   PubMed Web of Science ®Google Scholar
• Araki H, Suemaru K, Gomita Y. Neuronal nicotinic receptor and psychiatric disorders: functional and behavioral effects of nicotine. Jpn J Pharmacol 2002;88:133–8
   Google Scholar
• Greene JG, Smith R, Gardiner M, Timbury GC. Measuring behavioural disturbance of elderly demented patients in the community and its effects on relatives: a factor analytic study. Age Ageing 1982;11:121–6
   PubMedGoogle Scholar
• Pang FC, Chow TW, Cummings JL, et al. Effect of neuro-psychiatric symptoms of Alzheimer’s disease on Chinese and American caregivers. Int J Geriatr Psychiatry 2002;17(1):29–34
   PubMed Web of Science ®Google Scholar